Date

Thursday, 26 September 2013

Location

European Medicines Agency, Amsterdam, the Netherlands

Representatives from patients', consumers' and healthcare professionals' organisations, together with the European Federation of Pharmaceutical Industries and Associations, and Committee for Medicinal Products for Human Use and Pharmacovigilance Risk Assessment Committee representatives, are meeting to discuss the different ways of involving patients in benefit / risk assessments, from the early stages of development of a medical product, through to its authorisation and beyond. Registration by invitation only.

Documents

Share this page